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of Madrid, SpainBackground & Aims: The relationship between acute-on- Several factors have been proposed to identify patients with
chronic liver failure (ACLF) and acute variceal bleeding (AVB) is
poorly understood. Specifically, the prevalence and prognosis of
ACLF in the context of AVB is unclear, while the role of trans-
jugular intrahepatic portosystemic shunt (TIPS) in the manage-
ment in patients with ACLF has not been described to date.
Methods: A multicenter, international, observational study was
conducted in 2,138 patients from 34 centers between 2011 and
2015. ACLF was defined and graded according to the EASL-CLIF
consortium definition. Placement of pre-emptive TIPS (pTIPS)
was based on individual center policy. Patients were followed-up
for 1 year, until death or liver transplantation. Cox regression and
competing risk models (Gray’s test) were used to identify inde-
pendent predictors of rebleeding or mortality.
Results: At admission, 380/2,138 (17.8%) patients had ACLF ac-
cording to EASL-CLIF criteria (grade 1: 38.7%; grade 2: 39.2%;
grade 3: 22.1%). The 42-day rebleeding (19% vs. 10%; p <0.001)
and mortality (47% vs. 10%; p <0.001) rates were higher in pa-
tients with ACLF and increased with ACLF grades. Of note, the
presence of ACLF was independently associated with rebleeding
and mortality. pTIPS placement improved survival in patients
with ACLF at 42 days and 1 year. This effect was also observed in
propensity score matching analysis of 66 patients with ACLF, of
whom 44 received pTIPs and 22 did not.
Conclusions: This large multicenter international real-life study
identified ACLF at admission as an independent predictor of
rebleedingandmortality inpatientswithAVB.Moreover, pTIPSwas
associated with improved survival in patients with ACLF and AVB.
Lay summary: Acute variceal bleeding is a deadly complication
of liver cirrhosis that results from severe portal hypertension.
This study demonstrates that the presence of acute-on-chronic
liver failure (ACLF) is the strongest predictor of mortality in pa-
tients with acute variceal bleeding. Importantly, patients with
ACLF and acute variceal (re)bleeding benefit from pre-emptive
(early) placement of a transjugular intrahepatic portosystemic
shunt.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Acute variceal bleeding (AVB), which accounts for 70% of all
upper gastrointestinal bleeding episodes in cirrhosis,1 has been
identified as a common cause of death in patients with cirrhosis,
with a 6-week mortality around 20%.2 At present, progress has
been made in the treatment of AVB, including endoscopic
treatment, drug therapy, and transjugular intrahepatic porto-
systemic shunt (TIPS).3,4 However, 10–20% of patients with AVB
experience treatment failure after initial endoscopic and medical
treatment, which is associated with a high short-term risk of
further liver decompensation and death.5Journal of Hepatology 20AVB who are at high risk of poor outcomes and treatment
failure, such as the model for end-stage liver disease (MELD)
score, renal failure, bacterial infection and active bleeding at
endoscopy.2,6,7 The Baveno VI Consensus recommends the use
of pre-emptive TIPS (pTIPS) in cirrhotic patients with Child-
Pugh B cirrhosis and active bleeding at endoscopy despite
being on vasoactive drugs, and in patients with Child-Pugh C
(<14 points).8 Several studies have shown that pTIPS placed
within 24–72 hours after admission, leads to a significant
improvement in relevant clinical outcomes.5,9–12 pTIPS pre-
vents rebleeding and ascites without increasing the compli-
cation of hepatic encephalopathy (HE),13 and is thus a
milestone in the treatment of cirrhotic patients with AVB. The
benefits of pTIPS probably rely on the prevention of further
deterioration after failure of initial treatment, avoiding subse-
quent increase in rebleeding, organ failure and death.14 This
condition frequently meets the criteria of acute-on-chronic
liver failure (ACLF), which comprises a rapidly deteriorating
syndrome with extremely high short-term mortality.15 With a
prevalence of over 22%, ACLF is common in cirrhotic patients
with acute decompensation.15,16 AVB is a well-known trigger
for the development of ACLF.17,18 However, the role of ACLF in
the outcome of patients with AVB has not yet been
investigated.
This multicenter, international, observational study addresses
3 clinically relevant issues: i) the prevalence of ACLF at admission
in patients with AVB; ii) the influence of ACLF at admission on
AVB outcomes (rebleeding and mortality); iii) the impact of
pTIPS on mortality of patients with ACLF and AVB.Patients and methods
Study design and patients
This study has been conducted using the database of a multi-
center, international, prospective observational study by the
Baveno Cooperation to evaluate AVB in cirrhotic patients in 34
centers between October 2011 and May 2015. The study protocol
(see supplementary information and CTAT table) and details
were published previously.13 All patients were managed ac-
cording to the guidelines of the Baveno V consensus and the
AASLD guidelines.19 Patients at high risk of variceal rebleeding,
i.e. with either Child-Pugh grade C cirrhosis, or grade B cirrhosis
with active bleeding at endoscopy despite the use of vasoactive
agents, were considered for pTIPS based on individual center
policy.5
Patients were regularly followed-up for 1 year, until death,
liver transplantation, or the end date of follow-up, whichever
came first. Medical history, clinical, biochemistry and endoscopic
findings, treatments and outcomes were recorded during hos-
pitalization. The primary outcome of this study was all-cause20 vol. 73 j 1082–1091 1083
Table 1. Baseline characteristics of all patients and patients with or without ACLF.
Baseline characteristics All patients
(n = 2138)
ACLF
(n = 380)
Non-ACLF
(n = 1758)
p value
Male, n (%) 1,570 (73.4) 286 (75.3) 1,284 (73.1) 0.382
Age 58.0 (50.0–68.0) 57.0 (50.0–67.8) 59.0 (50.0–68.0) 0.356
Etiology of cirrhosis, n (%),
Alcohol/virus/alcohol & virus/others
1,006/508/282/342
(47.1/23.7/13.2/15.9)
216/71/45/48
(56.8/18.7/11.9/12.6)
790/437/237/294
(45.0/24.8/13.5/16.8)
<0.001
Hepatocellular carcinoma, n (%) 129 (6.0) 24 (6.3) 105 (6.0) 0.799
Portal vein thrombosis, n (%) 33 (15.6) 273 (15.8) 60 (16.0) 0.938
Previous bleeding, n (%) 671 (31.4) 93 (24.5) 578 (32.9) 0.001
Previous episode of decompensation, n (%)
Ascites 1013 (47.4) 237 (62.4) 776 (44.1) <0.001
Hepatic encephalopathy 323 (15.1) 111 (29.2) 212 (12.1) <0.001
Spontaneous bacterial peritonitis/bacteremia 123 (5.8) 52 (13.7) 71 (4.0) <0.001
Hepatorenal syndrome 40 (1.9) 22 (5.8) 18 (1.0) <0.001
Decompensation at admission
Ascites 866 (40.5) 162 (42.6) 704 (40.0) 0.357
Hepatic encephalopathy 618 (28.9) 220 (57.9) 398 (22.6) <0.001
Bacterial infection 368 (17.2) 132 (34.7) 236 (13.4) <0.001
Laboratory tests
Hemoglobin (g/L) 85.0 (66.0–101.0) 78.0 (65.0–93.0) 87.0 (67.0–104.0) <0.001
Leucocytes (109/L) 7.7 (5.5–11.1) 9.1 (6.0–14.6) 7.5 (5.3–10.5) <0.001
Platelet count (109/L) 97.0 (67.0–138.8) 90.0 (64.0–136.0) 98.0 (68.0–139.0) 0.013
Creatinine (mg/dl) 0.9 (0.7–1.2) 1.7 (1.0–2.5) 0.8 (0.7–1.0) <0.001
Urea nitrogen (mg/dl) 49.0 (30.0–76.0) 82.0 (43.0–132.0) 46.0 (28.0–68.0) <0.001
Na (mEq/L) 137.0 (134.0–140.0) 136.0 (131.0–140.0) 138.0 (134.0–140.0) <0.001
Bilirubin (mg/dl) 1.7 (1.0–3.1) 2.9 (1.2–7.3) 1.6 (0.9–2.7) <0.001
Albumin (g/L) 27.1 (23.2–31.0) 26.0 (21.1–30.0) 28.0 (24.0–32.0) <0.001
AST (U/L) 53.0 (33.0–95.0) 66.0 (36.0–128.8) 50.0 (33.0–90.0) <0.001
ALT (U/L) 33.0 (21.0–52.0) 36.0 (22.0–63.5) 32.0 (21.0–50.0) 0.006
INR 1.4 (1.3–1.7) 1.7 (1.4–2.4) 1.4 (1.2–1.6) <0.001
Glucose (mg/dl) 139.0 (112.0–187.3) 140.0 (110.8–180.5) 139.0 (113.0–189.0) 0.257
Organ failures, n (%) <0.001
Circulatory failure 233 (10.9) 202 (53.2) 31 (1.8)
Respiratory failure 232 (10.9) 169 (44.5) 63 (3.6)
Cerebral failure 219 (10.2) 117 (30.8) 102 (5.8)
Renal failure 163 (7.6) 163 (42.9) 0 (0.0)
Coagulation failure 112 (5.2) 89 (23.4) 23 (1.3)
Liver failure 82 (3.8) 66 (17.4) 16 (0.9)
Length of ICU stay (days) (686/227/459) 5 (2–10) 7 (3–12) 4 (2–8) <0.001
Scores
MELD 11.7 (7.6–16.7) 21.4 (17.0–27.4) 10.3 (6.8–14.1) <0.001
Child-Pugh 8.0 (7.0–10.0) 10.0 (8.0–12.0) 8.0 (7.0–9.0) <0.001
Child-Pugh class (A/B/C), n (%) 468/1,102/568
(21.9/51.5/26.6)
45/136/199
(11.8/35.8/52.4)
423/966/369
(24.1/54.9/21.0)
<0.001
ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICU, intensive care unit; INR, international normalized ratio; MELD, model
for end-stage liver disease.
Mann-Whitney U test.
Research Article Cirrhosis and Liver Failuremortality or liver transplantation at day 42 and 1 year. The
secondary outcome was rebleeding.
In this secondary ancillary study, we analyzed the influence of
ACLF at admission in variceal bleeding evolution and the role of
pTIPS on the outcomes of patients with ACLF.
For this purpose, ACLF at admission was retrospectively
defined and graded according to the EASL-CLIF consortium
definition (supplementary methods).15 Briefly, liver, kidney and
coagulation failure were assessed by bilirubin, creatinine and
international normalized ratio (INR) levels that were specifically
included in the electronic case report form (CRF). Brain failure
was evaluated by HE grades (West Haven). Circulatory failure
was considered when vasopressor therapy was needed to
maintain blood pressure. A total of 233 patients treated with
vasoactive drugs to maintain blood pressure were defined as
having circulatory failure. Finally, respiratory failure (n = 232)
was diagnosed when mechanical ventilation was required for1084 Journal of Hepatology 20reasons other than airway protection and in the absence of HE
grade III or IV. Renal replacement therapy was not recorded in
any patients, at least at enrollment, but renal dysfunction and
failure were based on creatinine values, as defined by the
EASL-CLIF ACLF definition. A total of 686 patients were admitted
to the intensive care unit (ICU) and the length of ICU stay was
recorded, with a median of 5 days.
For the specific analysis of the impact of the relationship
between pTIPS in ACLF, patients were excluded if they were older
than 75 years, had developed hepatocellular carcinoma outside
the Milan criteria, had active sepsis, creatinine levels >−3 mg/dl,
heart failure or complete portal vein thrombosis. Only patients
who fulfilled the prespecified criteria for pTIPS were included in
the analysis on pTIPS (Fig. S1).
The ethics committees of all participating hospitals approved
the study protocol and all participants included in the study
provided written informed consent.20 vol. 73 j 1082–1091
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Fig. 1. ACLF and risk factors for rebleeding in patients with variceal bleeding. (A) Cumulative incidence function curve of 42-day cumulative rebleeding rate in
patients with and without ACLF. Levels of significance: p <0.0001 (Gray’s test). (B) Cumulative incidence function curve of 1-year cumulative rebleeding rate in
patients with and without ACLF. Levels of significance: p = 0.024 (Gray’s test). (C) Independent risk factors of 42-day rebleeding in all patients with acute variceal
bleeding. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). (D) Independent risk factors of 1-year
rebleeding in all patients with acute variceal bleeding. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox
model). ACLF, acute-on-chronic liver failure.Data management and statistical analysis
Multiple excellence control procedures were used to optimize
data quality. This included the use of a unified REDCap electronic
data capture system to record and manage data. Additionally, a
steering committee was formed to monitor data consistency and
correctness.
We followed the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) guideline for reporting
observational studies. Continuous variables were described as
median and interquartile range, and categorical variables as
frequency and percentage. Non-parametric Mann-Whitney U
test or Fisher’s exact test were used to compare groups of pa-
tients where appropriate. Cumulative incidence function curve
with Gray’s test were used for survival analysis. Univariate and
multivariate competitive risk Cox regression models were used
to identify independent predictors of 42-day and 1-year
rebleeding (liver transplantation or death as competing risks)
or mortality (with liver transplantation as competing risks). Po-
tential risk factors that were significant (p <0.05) in the univar-
iate competitive risk Cox regression analysis were included in a
multivariate analysis to analyze the subdistribution hazard ratioJournal of Hepatology 20(sHR). To confirm the robustness of our results, we performed a
sensitivity analysis comparing patients with ACLF receiving
pTIPS with those not receiving pTIPS by propensity score
matching (1:2).
A 2-tailed p value of <0.05 was considered statistically sig-
nificant. All statistical analyses were performed using the SAS
software (version 9.4; SAS Institute Inc., Cary, NC) or SPSS
(version 19.0; IBM, Chicago, IL).
Results
Baseline characteristics and the prevalence of ACLF at
admission in patients with AVB
We included a total of 2,138 patients (Fig. S1). Their baseline
characteristics are shown in Table 1. Patients were predomi-
nantly male (73.4%), with a median age of 58 years. Alcohol was
the most common etiology of liver disease. Of all the patients
included, 380 (17.8%) had ACLF at baseline (147 [38.7%], 149
[39.2%] and 84 [22.1%] had ACLF grade 1, 2 and 3, respectively).
Age and gender were similar between patients with and without
ACLF, but more patients with ACLF had an alcoholic etiology. As
expected, patients with ACLF more frequently presented with20 vol. 73 j 1082–1091 1085
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Research Article Cirrhosis and Liver Failureascites, spontaneous bacterial peritonitis, bacterial infections, HE
and hepatorenal syndrome, as well as significantly higher MELD
and Child-Pugh scores at baseline. However, patients with ACLF
had a significantly lower rate of previous bleeding, but a similar
rate of primary prophylaxis compared to patients without ACLF
(27.6% vs. 24.4%, p = 0.192).
ACLF as an independent risk factor of 42-day and 1-year
rebleeding and mortality in patents with AVB
Patients with ACLF had a higher rate of rebleeding compared to
patients without ACLF (42-day: 19.1% vs. 10.1%, p <0.001; 1-year:
22.9% vs. 17.7%, p = 0.024) (Fig. 1A and B). The risk of rebleeding
increased in line with ACLF grade (Fig. S2A).
Presence of ACLF, bacterial infection and non-occlusive or
non-tumoral portal vein thrombosis at admission were inde-
pendently associated with 42-day (multivariate ACLF: sHR 1.798;
95% CI 1.336–2.418; p <0.001) and 1-year rebleeding (multivar-
iate ACLF: sHR 1.535; 95% CI 1.183–1.992; p = 0.001). Hemoglobin
appeared as a protective factor for the risk of rebleeding at 42
days (Fig. 1C,D, Table 2).
As expected, patients with ACLF were more prone to die than
patients without ACLF (42-day: 47.1% vs. 10.0%; p <0.001, 1-year:
55.0% vs. 23.1%, p <0.001) (Fig. 2A,B), and mortality increased in
line with severity of ACLF (Fig. S2B). These effects of ACLF on
survival remained independent after adjusting for confounders
(Fig. 2C,D, Table 2). Other independent risk factors associated
with both 42-day and 1-year mortality were age, Child-Pugh
score, bacterial infection, hepatocellular carcinoma within
Milan criteria and blood urea nitrogen at baseline.
Impact of pre-emptive TIPS on rebleeding rate and mortality
in patients with AVB, with or without ACLF
In the subgroup analysis of patients eligible for pTIPS, a total of
66 patients underwent pTIPS, of whom 22 (33.3%) had ACLF
(Fig. S1). There were more patients with ACLF Grade III, who did
not receive TIPS. While patients with ACLF receiving pTIPS had
lower creatinine and glucose levels at baseline than patients
with ACLF who did not receive pTIPS, there were no significant
differences in age, gender, Child-Pugh score and other baseline
characteristics (Table 3).
pTIPS placement was independently associated with a lower
42-day rebleeding rate (HR 0.128; 95% CI 0.017–0.937; p = 0.043)
in patients with ACLF and treatment with pTIPS in these patients
reduced the risk of rebleeding due to ACLF (Fig. 3A,B and
Table S1).
Regarding mortality and in cases where the analysis was
restricted to patients with ACLF, patients treated with pTIPS had
a significantly lower 42-day and 1-year mortality than patients
receiving standard of care (Fig. 4A). Mortality was significantly
lower in the pTIPS compared to the non-pTIPS group of patients
with ACLF (42-day: 13.6% vs. 51.0%, p = 0.002; 1-year: 22.7% vs.
56.5%, p = 0.002). Treatment with pTIPS reduced 42-day
(multivariate sHR 0.22; 95% CI 0.07–0.74; p = 0.014) and 1-year
(multivariate sHR 0.33; 95% CI 0.12–0.92; p = 0.034) mortality
after adjustment for confounders (Fig. 4C,D, Table S1). Similar
results were observed after adjusting for CLIF-C ACLF score
instead of Child-Pugh score in the competitive Cox regression
model for 42-day and 1-year mortality (Table S2). When we
limited our analysis to patients with bilirubin over 5 mg/dl, pTIPS
significantly increased the survival rate in patients with ACLF,
regardless of hyperbilirubinemia (Fig. S3).20 vol. 73 j 1082–1091
A B
C D
Non-ACLF
ACLF
ACLF
Non-ALCF
N° at risk
1,758
380
1,616
287
1,530
237
1,479
212
1,444
190
1,413
190
1,388
168 ACLF
Non-ALCF
N° at risk
1,758
380
1,429
179
1,321
158
1,247
148
1,182
139
1,122
134
1,046
128
983
124
944
115
915
113
881
108
833
104
694
89
Gray’s test p <0.0001
HR 3.394 [2.844 to 4.052]HR 6.059 [4.922 to 7.459]
Gray’s test p <0.0001
0.0
2
4
6
8
0
Non-ACLF
ACLF
0.
0.
0.
0.
1.
C
um
ul
at
iv
e 
m
or
ta
lit
y 
ra
te
s
0.0
2
4
6
8
0
0.
0.
0.
0.
1.
C
um
ul
at
iv
e 
m
or
ta
lit
y 
ra
te
s
Follow-up Time (Weeks)
6543210 0 1110987654321 12
Follow-up time (Months)
1.0 1.1 5.0
Risk factors of 1-year mortality in all patients
Hazard ratio and 95% CI
p values
<0.001
<0.001
<0.001
<0.001
0.037
0.002
4.03.02.01.0 1.5 5.0 12.0
Risk factors of 42-day mortality in all patients
Hazard ratio and 95% CI
p values
0.044
<0.001
<0.001
<0.001
0.014
<0.001
0.027
4.03.02.0
Leucocyte (10x109/L) Hepatocellular carcinoma
Bacterial infection
ACLF
Child-Pugh score
Age (10 years)
Blood urea nitrogen
(10 mg/dl)
Hepatocellular carcinoma
ACLF
Infection at admission
Child-Pugh score
Age (10 years)
Blood urea nitrogen
(10 mg/dl)
Fig. 2. ACLF and risk factors for mortality in patients with variceal bleeding. (A) Cumulative incidence function curve of 42-day mortality patients with or
without ACLF. Levels of significance: p <0.0001 (Gray’s test). (B) Cumulative incidence function curve of 1-year mortality patients with or without ACLF. Levels of
significance: p <0.0001 (Gray’s test). (C) Independent risk factors of 42-day mortality in all patients with acute variceal bleeding. Levels of significance of each
significant covariate are marked in the figure (competitive risk Cox model). (D) Independent risk factors of 1-year mortality in all patients with acute variceal
bleeding. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model). ACLF, acute-on-chronic liver failure.In the absence of ACLF, patients treated with pTIPS also had
lower mortality, but without reaching statistical significance
(Table S3). Similar results can be seen in Fig. S4, showing the
competing risk analysis. It is important to remark that the study
was not designed to analyze this effect and it is underpowered
for this analysis.
To control for the severity of liver and extrahepatic dysfunc-
tion, we performed a propensity score matched sensitivity
analysis. The matched baseline characteristics of patients with
ACLF, treated with and without pTIPS, are shown in Table S4.
There were no significant differences between the 2 groups. In
this matched cohort, pTIPS significantly improved survival in
patients with ACLF, confirming the results observed in the un-
matched cohort (Fig. 4E).Discussion
This is the first study to describe the prevalence of ACLF and its
relationship with rebleeding and mortality in patients with AVB.
ACLF is an independent risk factor for rebleeding and mortality
in patients with AVB. Moreover, patients with ACLF and AVB may
benefit from placement of pTIPS.Journal of Hepatology 20ACLF is characterized by rapid deterioration of organ function
leading to multiple organ failures and high short-term mortal-
ity.15 AVB has been described as a precipitating event for
ACLF,15,20 but the role of ACLF on the outcomes associated with
AVB has not been investigated to date. We found that a sub-
stantial percentage of patients with AVB present with ACLF. One
in every 5–6 patients with AVB presented with or developed
ACLF.
One of the most important and clinically relevant findings of
this study was that ACLF almost doubled the risk of rebleeding,
providing an easy identification criterion for patients with
rebleeding risk. Interestingly, ACLF predicted this independently
of the presence of portal vein thrombosis, which is a well-known
risk factor for rebleeding described in several studies.21,22 These
facts show that our cohort data collection is consistent with the
literature, while confirming that our analysis is robust, despite
the limitations of the study design described below.
ACLF, not surprisingly, was associated with worse prognosis
in patients with AVB. However, to date, this has not been
investigated thoroughly. The CANONIC study, which character-
ized ACLF, demonstrated that bleeding occurs similarly in20 vol. 73 j 1082–1091 1087
Table 3. Comparison of baseline characteristics between patients with and without pre-emptive TIPS based on baseline ACLF status.
Baseline characteristics
ACLF
p value
Non-ACLF
p value
pTIPS
(n = 22)
No pTIPS
(n = 147)
pTIPS
(n = 44)
No pTIPS
(n = 458)
Male, n (%) 13 (59.1) 116 (78.9) 0.058 34 (77.3) 350 (76.4) 1.000
Age 53.0 (43.8–60.5) 54.0 (49.0–60.0) 0.522 53.0 (44.3–62.0) 55.0 (47.0–62.0) 0.300
Etiology of cirrhosis, n (%) 0.754 0.262
Alcohol liver disease 16 (72.7) 94 (64.0) 31 (70.5) 260 (56.8)
Hepatotropic virus 1 (4.5) 22 (15.0) 6 (13.6) 62 (13.5)
Alcohol and virus 3 (13.6) 23 (15.6) 5 (11.4) 80 (17.4)
Others 2 (9.1) 18 (5.4) 2 (4.5) 56 (12.2)
Hepatocellular carcinoma, n (%) 0 (0.0) 4 (2.7) 1.000 1 (2.3) 4 (0.9) 0.369
Previous bleeding, n (%) 6 (27.3) 34 (23.1) 0.788 11 (25.0) 156 (34.1) 0.245
Portal vein thrombosis 0 (0.0) 8 (5.5) 0.599 2 (4.5) 27 (6.0) 1.000
Previous episode of decompensation, n (%)
Ascites 13 (59.1) 90 (61.2) 1.000 19 (43.2) 238 (52.0) 0.274
Bacterial infection 5 (22.7) 55 (37.4) 0.235 6 (13.6) 91 (19.9) 0.424
Hepatic encephalopathy 7 (31.8) 48 (32.7) 1.000 8 (18.2) 67 (14.6) 0.509
Spontaneous bacterial
peritonitis/bacteremia
2 (9.1) 24 (16.3) 0.534 3 (6.8) 24 (5.2) 0.722
Hepatorenal syndrome 1 (4.5) 6 (4.1) 1.000 1 (2.3) 8 (1.7) 0.565
Laboratory test
Hemoglobin (g/L) 87.5 (51.0–101.3) 76.0 (63.0–90.0) 0.298 77.5 (60.0–90.3) 86.0 (68.0–101.0) 0.017
Leucocytes (109/L) 9.1 (6.7–12.9) 8.7 (6.1–14.1) 0.900 9.5 (6.3–12.7) 8.2 (5.8–11.6) 0.337
Platelet count (109/L) 76.0 (64.5–97.8) 79.0 (54.0–125.0) 0.835 89.0 (73.0–112.0) 83 (58.5–122.5) 0.296
Creatinine (mg/dl) 0.9 (0.6–1.4) 1.3 (0.8–1.8) 0.070 0.8 (0.7–1.1) 0.8 (0.6–1.0) 0.193
Urea nitrogen (mg/dl) 51.0 (24.6–91.0) 59.0 (36.0–105.0) 0.227 40.0 (18.5–51.7) 40.0 (24.8–64.0) 0.883
Na (mEq/L) 135.0 (132.9–139.8) 135.2 (131.0–140.0) 0.868 138.0 (134.1–140.8) 137.0 (134.0–140.0) 0.344
Bilirubin (mg/dl) 2.4 (1.7–5.3) 4.6 (2.1–13.0) 0.020 2.3 (1.7–4.4) 2.9 (1.7–4.5) 0.337
Albumin (g/L) 22.9 (20.6–27.9) 26.0 (22.0–29.0) 0.219 25.0 (21.3–27.2) 26.0 (22.0–29.0) 0.333
AST (U/L) 71.0 (51.0–164.0) 81.0 (48.0–143.0) 0.734 54.0 (39.0–97.0) 64.0 (41.0–112.0) 0.131
ALT (U/L) 50.0 (29.0–74.5) 39.0 (25.0–65.5) 0.386 23.0 (19.0–39.0) 34.0 (22.0–55.0) 0.025
INR 1.9 (1.6–2.4) 1.9 (1.6–2.6) 0.886 1.7 (1.5–1.8) 1.6 (1.4–1.9) 0.749
Glucose (mg/dl) 153.0 (129.0–234.5) 139.5 (103.7–171.5) 0.034 150.5 (113.5–197.8) 132.0 (109.0–173.0) 0.541
Scores
MELD 19.0 (13.0–22.0) 22.0 (17.0–26.0) 0.021 14.0 (10.0–17.0) 13.0 (10.0–17.0) 0.620
Child-Pugh 11.0 (10.0–11.0) 11.0 (10.0–12.0) 0.362 10.0 (9.0–11.0) 10.0 (8.0–11.0) 0.755
Child B, n (%) 3 (13.6) 27 (18.4) 0.769 16 (36.4) 191 (41.7) 0.525
Child C, n (%) 19 (86.4) 120 (81.6) 28 (63.6) 267 (58.3)
ACLF grades 0.043
1 8 (36.4) 50 (34.0) –
2 13 (59.1) 56 (38.1) –
3 1 (4.5) 41 (27.9) –
ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; MELD, model for end-stage liver
disease; pTIPS, pre-emptive transjugular intrahepatic portosystemic shunt.
Mann-Whitney U test.
Research Article Cirrhosis and Liver Failurepatients with and without ACLF. However, the present study is
the first to investigate the role of ACLF in patients with variceal
bleeding. Indeed, ACLF is, together with hepatocellular carci-
noma, the strongest predictor of short-term mortality in variceal
bleeding, with an almost 3-fold increased risk. These data are in
line with the data of the CANONIC study and, again, prove the
robustness of our study.15
Our results showed that ACLF is a major independent risk
factor for rebleeding and mortality and that it may justify or even
require more aggressive treatment. pTIPS has been introduced to
treat patients at high risk of treatment failure, identified either
by an hepatic venous pressure gradient over 20 mmHg, either a
Child-Pugh C or Child-Pugh B with active bleeding at endos-
copy.21,23,24 Previous studies using the latter criteria have shown
that pTIPS can improve the prognosis of patients with AVB,10,25
without increasing the risk of complications such as HE.13
There are currently no related studies discussing the relation-
ship between pTIPS and patients with ACLF. Our results suggest
that pTIPS could improve the survival of patients with ACLF1088 Journal of Hepatology 20remarkably. Both short-term and long-term mortality could be
halved in the patients who were treated with pTIPS. Therefore,
and considering the marked impact of pTIPS on rebleeding and
most importantly on short-term mortality, this therapeutic tool
should be considered in the management of patients with ACLF
and AVB, even in patients with bilirubin higher than 5 mg/dl. The
consequence of this hypothesis would be to transfer the affected
patients to hospitals with access to TIPS, thereby potentially
reducing their mortality rate by 75%. These data are nicely sup-
ported by a recent study which showed that the higher the MELD
score, the bigger the survival benefit after pTIPS.25 Despite a
reduction in mortality observed in patients without ACLF, the
statistical significance was not achieved. This is because mor-
tality in these patients is much lower and therefore the sample
size needed to demonstrate a potential significant benefit is
higher than the 44 patients evaluated. Further studies must
dissect the role of pTIPS in high-risk patients without ACLF.
These results could be confirmed after controlling for con-
founders using propensity score matching. However, this study20 vol. 73 j 1082–1091
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Fig. 3. Pre-emptive TIPS and risk factors for rebleeding in patients with ACLF and acute variceal bleeding. (A) Cumulative incidence function curve of 42-day
rebleeding rate in patients with ACLF, with or without pre-emptive TIPS. Levels of significance: p = 0.0285 (Gray’s test). (B) Risk factors for 42-day rebleeding in
patients with ACLF, with or without pre-emptive TIPS. Levels of significance of each significant covariate are marked in the figure (competitive risk Cox model).
ACLF, acute-on-chronic liver failure; TIPS, transjugular intrahepatic portosystemic shunt.had several limitations. While the data collection process of this
study is prospective, multi-centered and large-scale, it lacked the
on-site monitoring visit of a randomized control trial. Moreover,
ACLF was diagnosed retrospectively, since the study had been
planned before publication of the EASL-ACLF criteria. The precise
information on vasoactive drug use were retrieved from the
CRFs, and those patients treated with vasoactive drugs to
maintain blood pressure were defined as having circulatory
failure. Additionally, in the database, the need for mechanical
ventilation without HE grade III or IV at admission was reported
as respiratory failure. However, the result was confirmed by
propensity score matching and thus had a high degree of con-
sistency. Additionally, data regarding ACLF development after
variceal bleeding were not collected. Unfortunately, we cannot
clarify whether bleeding was the precipitating event of ACLF.
Still, we believe that the study is relevant in real clinical practice.
Another limitation of this study is the limited number of patients
with ACLF treated with pTIPS, even though this is the largest and
first study investigating pTIPS in this population. Further studies
assessing the role of pTIPS on outcomes in patients with ACLF are
needed to validate these results.
This large, multicenter, international study confirms that ACLF
is frequent in patients with AVB, that ACLF is an independent
predictor of rebleeding and mortality, and that pTIPS could
improve survival in patients with ACLF and AVB.Abbreviations
ACLF, acute-on-chronic liver failure; ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase; AVB, acute variceal
bleeding; HE, hepatic encephalopathy; HR, hazard ratio; ICU,
intensive care unit; INR, international normalized ratio; MELD,
model for end-stage liver disease; sHR, subdistribution HR;
pTIPS, pre-emptive TIPS; TIPS, transjugular intrahepatic porto-
systemic shunt.Journal of Hepatology 20Financial support
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